RayKnowChina Research Map
Shortlist

RecruitingCoronary heart diseasePhase 4

Registered title, quoted from ClinicalTrials.gov

Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

An open trial on coronary heart disease, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Nantong University南通大学附属医院NantongHospital page
  2. Study siteFuwai Hospital中国医学科学院阜外心血管病医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06425120, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months

    Exclusion criterion 2

  3. Progressive neuromuscular disease, or creatine kinase (CK) levels > 3 times the normal upper limit (ULN)

    Exclusion criterion 7

    Active liver disease, or alanine aminotransferase (ALT) levels > 3 times the upper limit of normal (ULN)

    Exclusion criterion 16

    Chronic kidney disease, or estimated glomerular filtration rate (eGFR) <60ml/ (min×1.73m2)

    Exclusion criterion 17

  4. Pregnancy or planned pregnancy, or breastfeeding

    Exclusion criterion 18

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06425120, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years old
  • Chronic coronary artery disease: meet any of the following conditions, and the condition is stable for at least 3 months:
  • History of myocardial infarction
  • Have received coronary interventional therapy
  • There are symptoms of myocardial ischemia (such as chest pain) and objective evidence (stress electrocardiogram or stress myocardial perfusion imaging indicated myocardial ischemia or coronary artery stenosis ≥50% )
  • High-sensitivity C-reactive protein ≥2mg/L
  • Currently taking moderate or above intensity statins lipid-lowering drugs
  • Currently taking antiplatelet drugs
  • Sign informed consent

Exclusion Criteria:

  • Patients fulfilling any of the following criteria are not eligible for inclusion in this trial:
  • Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months
  • Previously received coronary artery bypass grafting
  • Stroke occurred within the previous 3 months
  • Symptomatic heart failure (HF) in the past, or documented left ventricular ejection fraction < 35%
  • Revascularization or surgical procedures are planned within the next 3 months
  • Progressive neuromuscular disease, or creatine kinase (CK) levels > 3 times the normal upper limit (ULN)
  • Lupus, inflammatory bowel disease, severe arthritis and other inflammatory diseases
  • Immunosuppressants such as cyclosporine, tacrolimus, azathioprine, or systemic steroids are currently being taken or planned during the study
  • History of hereditary dyslipidemia such as familial hypercholesterolemia
  • There has been a change in lipid regulation treatment within the past 1 month, or there is a current adjustment plan
  • History of symptomatic non-traumatic cerebral hemorrhage at any time in the past
  • History of gastrointestinal bleeding or major surgery within the past 6 months
  • Use of Xuesaitong soft capsules or preparations containing the main ingredients of Xuesaitong in the past 1 month
  • There were clear adverse reactions to the main components of Xuesaitong in the past
  • Active liver disease, or alanine aminotransferase (ALT) levels > 3 times the upper limit of normal (ULN)
  • Chronic kidney disease, or estimated glomerular filtration rate (eGFR) <60ml/ (min×1.73m2)
  • Pregnancy or planned pregnancy, or breastfeeding
  • Malignant tumors, or other serious diseases with an estimated survival of less than 1 year
  • Mental disorders or communication disorders, cognitive impairment, or other serious medical conditions that may affect study participation
  • Have participated in or are participating in other clinical trials within the last 1 month
  • Poor adherence to follow-up or medication is known

Quoted from ClinicalTrials.gov, NCT06425120, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06425120, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06425120